首页> 中文期刊> 《中国医药导报》 >左卡尼汀辅助治疗透析前慢性肾衰竭患者贫血的疗效观察

左卡尼汀辅助治疗透析前慢性肾衰竭患者贫血的疗效观察

         

摘要

Objective: To observe the effects of L-camitine combined with erythropoietin (EPO) on treating patients with non-dialysis and assess whether combined therapy could increase the level of the Hb and Hct and decrease the requirement for exogenous erythropoietin and safety. Methods: sixty-two patients were randomly divided into two groups, 31 patients in treatment group were treated with regular dose EPO and L-camitine. 31 patients in control group were treated with regular dose EPO, the strategy was carried on for 8 weeks. Then the results of anemia and the risk of hypertension were compared in two groups. Results: The improvement of blood morphology parameters (Hb and Hct) were observed in each group after 4 weeks and 8 weeks, significant improvement appeared in treatment group than in control group (P<0.01),and less EPO was used in the treatment group, elevation incidence of blood pressure of treatment group decreased than that of control group. Conclusion: L-camition combined with erythropoietin can significantly improve nephritic anemia m nondialysis patients, and make patients more safety and useful.%目的:观察左卡尼汀辅助治疗慢性肾衰竭非透析患者肾性贫血的疗效和安全性.方法:采用随机对照研究,将我院2010年1~10月入院的慢性肾衰竭未透析患者62例随机分为两组.治疗组左卡尼汀辅助常规剂量重组人促红细胞生成素(EPO)治疗31例,对照组单用常规剂最蓖组人促红细胞生成素治疗31例.观察两组方法治疗4周及8周后贫血指标及血压等副反应的变化.结果:治疗组治疗后第4周血红蛋白及血细胞比容水平明显高于对照组,治疗第8周EPO用量明显减少,血压升高发生率比对照组亦有减少.结论:左卡尼汀可以明显提高EPO对透析前慢性肾衰竭患者贫血的疗效,且EPO用量减少,安全有效.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号